Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ProfoundBio Starts US Trial of ADC in Solid Tumor Cancers

publication date: Jan 3, 2023

ProfoundBio, a Seattle-Suzhou company, has begun a first-in-human US Phase I trial of a proprietary ADC in patients with solid tumor cancers. The candidate, PRO1184, is an ADC that combines a folate receptor alpha-directed antibody conjugated to the exatecan payload using ProfoundBio's proprietary hydrophilic linker (exatecan is a novel synthetic camptothecin derivative). In July 2022, ProfoundBio was approved to start a US Phase I of PRO1160, an ADC that joins a CD70-directed antibody to the exatecan payload. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital